<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 21-Feb | 06:00 - 07:00 AM   | Pharmacogenomics and   | Using HDAC Inhibitors to Improve Cancer Immunotherapy                              | Alejandro Villagra, PhD  
Assistant Professor of Biochemistry and Molecular Medicine, GW School of Medicine and Health Sciences |
|        |                    | Personalized Medicine  |                                                                                    |                                                                         |
| 21-Feb | 07:30 - 08:30 AM   | Pharmacogenomics and   | Keynote Presentation: Evolving Paradigms of Phamacogenomics and Personalized Medicine (Molecular Pathological Epidemiology) and Immuno-MPE for Precision Medicine | Shuji Ogino, MD, PhD, MS  
Chief, Program in MPE Molecular Pathological Epidemiology, Brigham and Women's Hospital, Professor of Pathology and Epidemiology, Harvard Medical School, Dana-Farber Cancer Institute |
|        |                    | Personalized Medicine  |                                                                                    |                                                                         |
| 21-Feb | 09:00 - 10:00 AM   | Biomarkers in Early    | Application of a Novel Cell Proliferation Biomarker in Cancer Drug Development: Immunoassay of Thymidine Kinase 1 in In-Vitro and In-Vivo Studies of Hematological and Solid Malignancies | Martin Shaw  
Business Development Manager at AroCell AB |
|        |                    | Stage Drug Development |                                                                                    |                                                                         |
| 21-Feb | 09:00 - 10:00 AM   | GPCR Drug Discovery    | New Tools for Understanding Allosteric Signaling in G Protein Coupled Receptors    | Matthew Eddy, PhD  
Postdoctoral Research Fellow, The Scripps Research Institute |
|        |                    |                        |                                                                                    |                                                                         |
| 21-Feb | 09:00 - 10:00 AM   | Pharmacogenomics and   | Transcriptomic Analysis of a Botanical Complex for the Topical Treatment of Atopic Dermatitis | Joe Sherrill, PhD  
Senior Scientist, Global Biosciences, Bioinformatics Group, The Procter & Gamble Company |
|        |                    | Personalized Medicine  |                                                                                    |                                                                         |
| 21-Feb | 10:30 - 11:30 AM   | Pharmacogenomics and   | Panel Discussion: Co-development of Drugs and Companion Diagnostics                | Annette Gilchrist, PhD  
Associate-Professor, Pharmaceutical Sciences, Midwestern University  
Martin Shaw  
Business Development Manager at AroCell AB  
Thomas Webster, PhD  
Professor and Department Chair, Chemical Engineering, Art Zafiropoulo Chair in Engineering, Affiliated Faculty, Bioengineering, Northeastern University, College of Engineering |
|        |                    | Personalized Medicine  |                                                                                    |                                                                         |
| 21-Feb | 10:30 - 11:30 AM | Emerging Trends | The Effects of Epigenetic Therapies on the Tumor and Host Immune System | Katherine Chiappinelli, PhD  
Assistant Professor of Microbiology, Immunology, & Tropical Medicine at The George Washington University |
| 21-Feb | 12:00 - 01:00 PM | GPCR Drug Discovery | Allosteric Modulation of Metabotropic Glutamate Receptors for the Treatment of Neurodevelopmental Disorders | Colleen Niswender, PhD  
Professor of Pharmacology, Director of Molecular Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery |
| 21-Feb | 12:00 - 01:00 PM | Pharmacogenomics and Personalized Medicine | Precision Medicine: Using Genotype to Inform Prescribing | Larisa Cavallari, Pharm. D.  
Associate Professor & Director, Center for Pharmacogenomics, University of Florida College of Pharmacy |
| 21-Feb | 01:30 - 02:30 PM | GPCR Drug Discovery | Can CADD Drive GPCR Drug Design? Rapid Estimation of Relative Binding Affinities Based on Pre-computed Ensembles | Alexander MacKerell, PhD  
Grollman-Glick Professor of Pharmaceutical Sciences, Director, Computer-Aided Drug Design Center, University of Maryland School of Pharmacy |
| 21-Feb | 01:30 - 02:30 PM | Emerging Trends | Liposomes for Drug Delivery and Targeting: Examples of Their Potential from Our Laboratories Research | Sophia Antimisiaris, PhD  
Professor, University of Patras & Institute of Chemical Engineering FORTH/ICE-HT |
| 22-Feb | 06:00 - 07:00 AM | Pharmacogenomics and Personalized Medicine | Developing Personalized Cancer Neoantigen Vaccines | Agnete Fredriksen, MSc, PhD  
Chief Scientific Officer, Vaccibody AS |
| 22-Feb | 06:00 - 07:00 AM | Emerging Trends | Testing for Soluble ST2: Opening New Perspectives for Cardiovascular Diseases | Damien Gruson, PhD  
Professor, Head of the Department of Clinical Biochemistry, Cliniques Universitaires Saint Luc |
| 22-Feb | 07:30 - 08:30 AM | Biomarkers in Early Stage Drug Development | Keynote Presentation: Predictive Biomarkers to Diagnostic Tests - Scientific and Regulatory Consideration in Development of Companion Diagnostic Tests | Janaki Veeraraghavan, PhD  
Biologist, CDRH/OIR/DMGP, U.S. Food and Drug Administration |
| 22-Feb | 09:00 - 10:00 AM | Pharmacogenomics and Personalized Medicine | Clinical Implementation of Pharmacogenomics: Delivering Genomics to the Bedside | Mark Dunnenberger, PharmD  
Director, Pharmacogenomics at NorthShore University HealthSystem |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Institution/Company</th>
</tr>
</thead>
</table>
| 22-Feb | 09:00 - 10:00 AM | Biomarkers in Early Stage Drug Development | Integrated Interrogation of Oncogenic Signaling Pathways, Immunology, and Heterogeneity in Cancer | Michael Davies, MD, PhD  
Deputy Chairman and Associate Professor in the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center  
Joseph M Beechem, PhD  
Senior Vice President of Research and Development, NanoString Technologies |
| 22-Feb | 10:30 - 11:30 AM | GPCR Drug Discovery      | Illuminating the Druggable GPCR-ome                                   | Bryan L. Roth, MD, PhD  
Michael Hooker Distinguished Professor, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy |
| 22-Feb | 10:30 - 11:30 AM | Emerging Trends           | Protective Effect of a Novel Noncompetitive IL-1 Receptor-Biased Ligand in an Infection - and Inflammation-Induced Preterm Birth as Well as in Fetal Injury and Developmental Outcomes | Sylvain Chemtob, MD, PhD, FRCPC, FAAP, FCAHS  
Professor of Pediatrics, Ophthalmology, Optometry and Pharmacology, Université de Montréal, Adjunct Professor of Pharmacology, McGill University, Université de Montréal |
| 22-Feb | 12:00 - 01:00 PM | Emerging Trends           | Commercializing Nanomedicine for Improving Human Health: Not Just Hype, It Is Really Happening! | Thomas Webster, PhD  
Professor and Department Chair, Chemical Engineering, Art Zafiropoulo Chair in Engineering, Affiliated Faculty, Bioengineering, Northeastern University, College of Engineering |
| 22-Feb | 12:00 - 01:00 PM | GPCR Drug Discovery        | New Structure Based Drug Design Opportunities for GPCRs and Related Transporters | Sid Topiol, PhD  
Chief Scientific Officer, 3D-2drug LLC |
| 22-Feb | 01:30 - 02:30 PM | GPCR Drug Discovery        | Recent Trends in GPCR Drug Discovery: Novel Targets, New Disease Indications, and an Upsurge in Biologics | Annette Gilchrist, PhD  
Associate-Professor, Pharmaceutical Sciences, Midwestern University |